Key Fields

Sequence Number:

Date Received: __ __ __ __ ­ __ __­ __ __
CIBMTR Center Number:

CIBMTR Research ID:

Event date: __ __ __ __ ­ __ __­ __ __
Visit

100 day 6 months 1 year 2 years > 2 years,

Specify:

Tepadina® Stop Date Questions: 1 ­ 2

Tepadina® stop date

Known Unknown

1

Date stopped:2 __ __ __ __ ­ __ __­ __ __

Hematologic Findings at Day 7 Post­HCT Questions: 3 ­ 13

Were blood counts tested at day 7? (post­HCT)

Yes No

3

Date of blood count:4 __ __ __ __ ­ __ __­ __ __
WBC

Known Unknown

5

WBC:6 x 109/L (x 103/mm3)

x 106/L

Neutrophils

Known Unknown

7

Neutrophils:8 %

Hemoglobin

Known Unknown

9

Hemoglobin:10 g/dL g/L mmol/L

Platelets

Known Unknown

11

Platelets:12 x 109/L (x 103/mm3)

x 106/L

Were platelets transfused ≤ 7 days before date of test?

Yes No

13

Hematologic Findings at Day 14 Post­HCT Questions: 14 ­ 24

Were blood counts tested at day 14? (post­HCT)

Yes No

14

Date of blood count:15 __ __ __ __ ­ __ __­ __ __
WBC

Known Unknown

16

WBC:17 x 109/L (x 103/mm3)

x 106/L

Neutrophils

Known Unknown

18

Neutrophils:19 %

Hemoglobin

Known Unknown

20

Hemoglobin:21 g/dL g/L mmol/L

Platelets

Known Unknown

22

Platelets:23 x 109/L (x 103/mm3)

x 106/L

Were platelets transfused ≤ 7 days before date of test?

Yes No

24

Hematologic Findings at Day 21 Post­HCT Questions: 25 ­ 35

Were blood counts tested at day 21? (post­HCT)

Yes No

25

Date of blood count:26 __ __ __ __ ­ __ __­ __ __
WBC

Known Unknown

27

WBC:28 x 109/L (x 103/mm3)

x 106/L

Neutrophils

Known Unknown

29

Neutrophils:30 %

Hemoglobin

Known Unknown

31

Hemoglobin:32 g/dL g/L mmol/L

Platelets

Known Unknown

33

Platelets:34 x 109/L (x 103/mm3)

x 106/L

Were platelets transfused ≤ 7 days before date of test?

Yes No

35

Organ Function Questions: 36 ­ 67

Did the recipient experience thiotepa related hypersensitivity reaction during HCT?

Yes No

36

Date of onset:37 __ __ __ __ ­ __ __­ __ __
Grade

1 2 3 4

38

In the transplant physician's judgment, was the disorder / impairment a direct result of the Tepadina® administration?

Yes No

39

Did the recipient develop an erythematous rash / toxic skin reaction?

Yes No

40

Date of onset:41 __ __ __ __ ­ __ __­ __ __
Symptoms (check all that apply)

Erythematous rash

Flushing

Photosensitivity

Stevens­Johnson syndrome / Toxic epidermal necrolysis

42

In the transplant physician's judgment, was the disorder / impairment a direct result of the Tepadina® administration?

Yes No

43

Did the recipient experience grade 3­4 elevation of AST, ALT, and/or bilirubin?

Yes No

44

Date of onset:45 __ __ __ __ ­ __ __­ __ __
In the transplant physician's judgment, was the disorder / impairment a direct result of the Tepadina® administration?

Yes No

46

Leukoencephalopathy

Yes No

47

Date of onset:48 __ __ __ __ ­ __ __­ __ __
In the transplant physician's judgment, was the disorder / impairment a direct result of the Tepadina® administration?

Yes No

49

Other neurological toxicity

Yes No

50

Specify other neurological toxicity:51

Date of onset:52 __ __ __ __ ­ __ __­ __ __
In the transplant physician's judgment, was the disorder / impairment a direct result of the Tepadina® administration?

Yes No

53

Confusion / delirium

Yes No

54

Date of onset:55 __ __ __ __ ­ __ __­ __ __
In the transplant physician's judgment, was the disorder / impairment a direct result of the Tepadina® administration?

Yes No

56

Hallucination

Yes No

57

Date of onset:58 __ __ __ __ ­ __ __­ __ __
In the transplant physician's judgment, was the disorder / impairment a direct result of the Tepadina® administration?

Yes No

59

Hemorrhage

Yes No

60

Date of onset:61 __ __ __ __ ­ __ __­ __ __
In the transplant physician's judgment, was the disorder / impairment a direct result of the Tepadina® administration?

Yes No

62

Cerebral hemorrhage

Yes No

63

Date of onset:64 __ __ __ __ ­ __ __­ __ __
In the transplant physician's judgment, was the disorder / impairment a direct result of the Tepadina® administration?

Yes No

65

In the transplant physician's judgment, were any of the disorders / impairments reported on the form 2100 a direct result of the Tepadina® reported administration?66

Yes

No

Not Applicable (none reported on 2100)

Specify (check all that apply)

Acute renal failure requiring dialysis

Bronchiolitis obliterans

Congestive heart failure

Cryptogenic organizing pneumonia (COP / BOOP)

Deep vein thrombosis (DVT) / Pulmonary embolism (PE)

Diffuse alveolar hemorrhage

GVHD

Hypertension (HTN) requiring therapy

Infection

Mucositis requiring therapy

New malignancy

Non­infectious interstitial pneumonitis (IPn or ARDS) / idiopathic pneumonia syndrome (IPS)

VOD

67

(acute or chronic)

First Name:

Last Name:

E­mail address:

Date: __ __ __ __ ­ __ __­ __ __

Report any disorder / impairment that can be directly attributed to Tepadina®

Erythematous rash / toxic skin reactions

Liver function

Neurological

Psychiatric

Vascular

Questions 66 ­ 67 refer to data reported on form 2100, please ensure data reported here matches with form 2100.

Center:  CRID: 

Form 2540 R1.0: Tepadina® Supplemental Data Collection Form

CIBMTR Form 2540 revision 1.0 last updated Monday, July 23, 2018
Copyright(c) 2012 National Marrow Donor Program and

The Medical College of Wisconsin, Inc. All rights reserved. Page 1 / 3



Key Fields

Sequence Number:

Date Received: __ __ __ __ ­ __ __­ __ __
CIBMTR Center Number:

CIBMTR Research ID:

Event date: __ __ __ __ ­ __ __­ __ __
Visit

100 day 6 months 1 year 2 years > 2 years,

Specify:

Tepadina® Stop Date Questions: 1 ­ 2

Tepadina® stop date

Known Unknown

1

Date stopped:2 __ __ __ __ ­ __ __­ __ __

Hematologic Findings at Day 7 Post­HCT Questions: 3 ­ 13

Were blood counts tested at day 7? (post­HCT)

Yes No

3

Date of blood count:4 __ __ __ __ ­ __ __­ __ __
WBC

Known Unknown

5

WBC:6 x 109/L (x 103/mm3)

x 106/L

Neutrophils

Known Unknown

7

Neutrophils:8 %

Hemoglobin

Known Unknown

9

Hemoglobin:10 g/dL g/L mmol/L

Platelets

Known Unknown

11

Platelets:12 x 109/L (x 103/mm3)

x 106/L

Were platelets transfused ≤ 7 days before date of test?

Yes No

13

Hematologic Findings at Day 14 Post­HCT Questions: 14 ­ 24

Were blood counts tested at day 14? (post­HCT)

Yes No

14

Date of blood count:15 __ __ __ __ ­ __ __­ __ __
WBC

Known Unknown

16

WBC:17 x 109/L (x 103/mm3)

x 106/L

Neutrophils

Known Unknown

18

Neutrophils:19 %

Hemoglobin

Known Unknown

20

Hemoglobin:21 g/dL g/L mmol/L

Platelets

Known Unknown

22

Platelets:23 x 109/L (x 103/mm3)

x 106/L

Were platelets transfused ≤ 7 days before date of test?

Yes No

24

Hematologic Findings at Day 21 Post­HCT Questions: 25 ­ 35

Were blood counts tested at day 21? (post­HCT)

Yes No

25

Date of blood count:26 __ __ __ __ ­ __ __­ __ __
WBC

Known Unknown

27

WBC:28 x 109/L (x 103/mm3)

x 106/L

Neutrophils

Known Unknown

29

Neutrophils:30 %

Hemoglobin

Known Unknown

31

Hemoglobin:32 g/dL g/L mmol/L

Platelets

Known Unknown

33

Platelets:34 x 109/L (x 103/mm3)

x 106/L

Were platelets transfused ≤ 7 days before date of test?

Yes No

35

Organ Function Questions: 36 ­ 67

Did the recipient experience thiotepa related hypersensitivity reaction during HCT?

Yes No

36

Date of onset:37 __ __ __ __ ­ __ __­ __ __
Grade

1 2 3 4

38

In the transplant physician's judgment, was the disorder / impairment a direct result of the Tepadina® administration?

Yes No

39

Did the recipient develop an erythematous rash / toxic skin reaction?

Yes No

40

Date of onset:41 __ __ __ __ ­ __ __­ __ __
Symptoms (check all that apply)

Erythematous rash

Flushing

Photosensitivity

Stevens­Johnson syndrome / Toxic epidermal necrolysis

42

In the transplant physician's judgment, was the disorder / impairment a direct result of the Tepadina® administration?

Yes No

43

Did the recipient experience grade 3­4 elevation of AST, ALT, and/or bilirubin?

Yes No

44

Date of onset:45 __ __ __ __ ­ __ __­ __ __
In the transplant physician's judgment, was the disorder / impairment a direct result of the Tepadina® administration?

Yes No

46

Leukoencephalopathy

Yes No

47

Date of onset:48 __ __ __ __ ­ __ __­ __ __
In the transplant physician's judgment, was the disorder / impairment a direct result of the Tepadina® administration?

Yes No

49

Other neurological toxicity

Yes No

50

Specify other neurological toxicity:51

Date of onset:52 __ __ __ __ ­ __ __­ __ __
In the transplant physician's judgment, was the disorder / impairment a direct result of the Tepadina® administration?

Yes No

53

Confusion / delirium

Yes No

54

Date of onset:55 __ __ __ __ ­ __ __­ __ __
In the transplant physician's judgment, was the disorder / impairment a direct result of the Tepadina® administration?

Yes No

56

Hallucination

Yes No

57

Date of onset:58 __ __ __ __ ­ __ __­ __ __
In the transplant physician's judgment, was the disorder / impairment a direct result of the Tepadina® administration?

Yes No

59

Hemorrhage

Yes No

60

Date of onset:61 __ __ __ __ ­ __ __­ __ __
In the transplant physician's judgment, was the disorder / impairment a direct result of the Tepadina® administration?

Yes No

62

Cerebral hemorrhage

Yes No

63

Date of onset:64 __ __ __ __ ­ __ __­ __ __
In the transplant physician's judgment, was the disorder / impairment a direct result of the Tepadina® administration?

Yes No

65

In the transplant physician's judgment, were any of the disorders / impairments reported on the form 2100 a direct result of the Tepadina® reported administration?66

Yes

No

Not Applicable (none reported on 2100)

Specify (check all that apply)

Acute renal failure requiring dialysis

Bronchiolitis obliterans

Congestive heart failure

Cryptogenic organizing pneumonia (COP / BOOP)

Deep vein thrombosis (DVT) / Pulmonary embolism (PE)

Diffuse alveolar hemorrhage

GVHD

Hypertension (HTN) requiring therapy

Infection

Mucositis requiring therapy

New malignancy

Non­infectious interstitial pneumonitis (IPn or ARDS) / idiopathic pneumonia syndrome (IPS)

VOD

67

(acute or chronic)

First Name:

Last Name:

E­mail address:

Date: __ __ __ __ ­ __ __­ __ __

Report any disorder / impairment that can be directly attributed to Tepadina®

Erythematous rash / toxic skin reactions

Liver function

Neurological

Psychiatric

Vascular

Questions 66 ­ 67 refer to data reported on form 2100, please ensure data reported here matches with form 2100.

Center:  CRID: 

Form 2540 R1.0: Tepadina® Supplemental Data Collection Form

CIBMTR Form 2540 revision 1.0 last updated Monday, July 23, 2018
Copyright(c) 2012 National Marrow Donor Program and

The Medical College of Wisconsin, Inc. All rights reserved. Page 2 / 3



Key Fields

Sequence Number:

Date Received: __ __ __ __ ­ __ __­ __ __
CIBMTR Center Number:

CIBMTR Research ID:

Event date: __ __ __ __ ­ __ __­ __ __
Visit

100 day 6 months 1 year 2 years > 2 years,

Specify:

Tepadina® Stop Date Questions: 1 ­ 2

Tepadina® stop date

Known Unknown

1

Date stopped:2 __ __ __ __ ­ __ __­ __ __

Hematologic Findings at Day 7 Post­HCT Questions: 3 ­ 13

Were blood counts tested at day 7? (post­HCT)

Yes No

3

Date of blood count:4 __ __ __ __ ­ __ __­ __ __
WBC

Known Unknown

5

WBC:6 x 109/L (x 103/mm3)

x 106/L

Neutrophils

Known Unknown

7

Neutrophils:8 %

Hemoglobin

Known Unknown

9

Hemoglobin:10 g/dL g/L mmol/L

Platelets

Known Unknown

11

Platelets:12 x 109/L (x 103/mm3)

x 106/L

Were platelets transfused ≤ 7 days before date of test?

Yes No

13

Hematologic Findings at Day 14 Post­HCT Questions: 14 ­ 24

Were blood counts tested at day 14? (post­HCT)

Yes No

14

Date of blood count:15 __ __ __ __ ­ __ __­ __ __
WBC

Known Unknown

16

WBC:17 x 109/L (x 103/mm3)

x 106/L

Neutrophils

Known Unknown

18

Neutrophils:19 %

Hemoglobin

Known Unknown

20

Hemoglobin:21 g/dL g/L mmol/L

Platelets

Known Unknown

22

Platelets:23 x 109/L (x 103/mm3)

x 106/L

Were platelets transfused ≤ 7 days before date of test?

Yes No

24

Hematologic Findings at Day 21 Post­HCT Questions: 25 ­ 35

Were blood counts tested at day 21? (post­HCT)

Yes No

25

Date of blood count:26 __ __ __ __ ­ __ __­ __ __
WBC

Known Unknown

27

WBC:28 x 109/L (x 103/mm3)

x 106/L

Neutrophils

Known Unknown

29

Neutrophils:30 %

Hemoglobin

Known Unknown

31

Hemoglobin:32 g/dL g/L mmol/L

Platelets

Known Unknown

33

Platelets:34 x 109/L (x 103/mm3)

x 106/L

Were platelets transfused ≤ 7 days before date of test?

Yes No

35

Organ Function Questions: 36 ­ 67

Did the recipient experience thiotepa related hypersensitivity reaction during HCT?

Yes No

36

Date of onset:37 __ __ __ __ ­ __ __­ __ __
Grade

1 2 3 4

38

In the transplant physician's judgment, was the disorder / impairment a direct result of the Tepadina® administration?

Yes No

39

Did the recipient develop an erythematous rash / toxic skin reaction?

Yes No

40

Date of onset:41 __ __ __ __ ­ __ __­ __ __
Symptoms (check all that apply)

Erythematous rash

Flushing

Photosensitivity

Stevens­Johnson syndrome / Toxic epidermal necrolysis

42

In the transplant physician's judgment, was the disorder / impairment a direct result of the Tepadina® administration?

Yes No

43

Did the recipient experience grade 3­4 elevation of AST, ALT, and/or bilirubin?

Yes No

44

Date of onset:45 __ __ __ __ ­ __ __­ __ __
In the transplant physician's judgment, was the disorder / impairment a direct result of the Tepadina® administration?

Yes No

46

Leukoencephalopathy

Yes No

47

Date of onset:48 __ __ __ __ ­ __ __­ __ __
In the transplant physician's judgment, was the disorder / impairment a direct result of the Tepadina® administration?

Yes No

49

Other neurological toxicity

Yes No

50

Specify other neurological toxicity:51

Date of onset:52 __ __ __ __ ­ __ __­ __ __
In the transplant physician's judgment, was the disorder / impairment a direct result of the Tepadina® administration?

Yes No

53

Confusion / delirium

Yes No

54

Date of onset:55 __ __ __ __ ­ __ __­ __ __
In the transplant physician's judgment, was the disorder / impairment a direct result of the Tepadina® administration?

Yes No

56

Hallucination

Yes No

57

Date of onset:58 __ __ __ __ ­ __ __­ __ __
In the transplant physician's judgment, was the disorder / impairment a direct result of the Tepadina® administration?

Yes No

59

Hemorrhage

Yes No

60

Date of onset:61 __ __ __ __ ­ __ __­ __ __
In the transplant physician's judgment, was the disorder / impairment a direct result of the Tepadina® administration?

Yes No

62

Cerebral hemorrhage

Yes No

63

Date of onset:64 __ __ __ __ ­ __ __­ __ __
In the transplant physician's judgment, was the disorder / impairment a direct result of the Tepadina® administration?

Yes No

65

In the transplant physician's judgment, were any of the disorders / impairments reported on the form 2100 a direct result of the Tepadina® reported administration?66

Yes

No

Not Applicable (none reported on 2100)

Specify (check all that apply)

Acute renal failure requiring dialysis

Bronchiolitis obliterans

Congestive heart failure

Cryptogenic organizing pneumonia (COP / BOOP)

Deep vein thrombosis (DVT) / Pulmonary embolism (PE)

Diffuse alveolar hemorrhage

GVHD

Hypertension (HTN) requiring therapy

Infection

Mucositis requiring therapy

New malignancy

Non­infectious interstitial pneumonitis (IPn or ARDS) / idiopathic pneumonia syndrome (IPS)

VOD

67

(acute or chronic)

First Name:

Last Name:

E­mail address:

Date: __ __ __ __ ­ __ __­ __ __

Report any disorder / impairment that can be directly attributed to Tepadina®

Erythematous rash / toxic skin reactions

Liver function

Neurological

Psychiatric

Vascular

Questions 66 ­ 67 refer to data reported on form 2100, please ensure data reported here matches with form 2100.

Center:  CRID: 

Form 2540 R1.0: Tepadina® Supplemental Data Collection Form

CIBMTR Form 2540 revision 1.0 last updated Monday, July 23, 2018
Copyright(c) 2012 National Marrow Donor Program and

The Medical College of Wisconsin, Inc. All rights reserved. Page 3 / 3